MS Speaks

From PubMed (November 22, 2020)--"Progressive multifocal leucoencephalopathy and the spectrum of JC virus-related disease," an abstract of a study appearing in Nature and done by investigators at the National Institutes of Health:


https://pubmed.ncbi.nlm.nih.gov/33219338/


Excerpt from the abstract:

Antiretroviral therapies greatly reduce the risk of HIV-related PML, but many modern treatments for cancers, organ transplantation and chronic inflammatory disease cause immunosuppression that can be difficult to reverse. These treatments - most notably natalizumab for multiple sclerosis - have led to a surge of iatrogenic PML. The spectrum of presentations of JCV-related disease has evolved over time and may challenge current diagnostic criteria. Immunotherapeutic interventions, such as use of checkpoint inhibitors and adoptive T cell transfer, have shown promise but caution is needed in the management of immune reconstitution inflammatory syndrome, an exuberant immune response that can contribute to morbidity and death.[/size] [/color][/size]

[/size]
[/size][size=78%][Emphasis added][/size]